#USA #Boston #animal testing #Lindsey Borton #Lush Prize

Gradient Recognizes Lindsey Borton as Lush Prize Finalist

In an exciting announcement, Gradient LLC declared that Principal Toxicologist Lindsey Borton has been named a finalist for the esteemed 2026 Lush Prize. Alongside her peer, Kelly Coleman, a distinguished toxicologist from Medtronic, Borton is recognized for her significant contributions to the field of toxicology, particularly regarding alternatives to traditional animal testing.

The Lush Prize is an influential award that aims to promote non-animal testing methods and recognize those who advocate for the end of animal use in research and education. Borton and Coleman have shown exceptional dedication in highlighting the limitations of animal-based tests, particularly in the context of medical devices. Their findings have been documented in an article published in the journal Alternatives to Animal Experimentation (ALTEX).

Evidence-Based Toxicology Approach

The research conducted by Borton and Coleman focuses on the concept of material-mediated pyrogens (MMPs) in medical devices. They explored whether MMPs could be effectively identified through the rabbit pyrogen test (RPT), a traditional method utilized in this field. Their work indicates the possibility of reducing reliance on animal testing without compromising the safety and efficacy of medical devices.

In their paper titled "Material-mediated pyrogens in medical devices: Myth or reality?" the authors presented compelling evidence that challenges long-standing assumptions about animal-based testing methodologies. This novel approach not only has the potential to transform how medical device safety is assessed but also encourages a wider adoption of non-animal alternatives across the industry.

About Lindsey Borton

Lindsey Borton is a Principal Toxicologist at Gradient, where her expertise lies in medical device biological safety and risk assessment. With a strong background in toxicology, Borton's role encompasses developing strategies that align with the rigorous standards set forth by regulatory bodies like the US Food and Drug Administration (FDA) and various international entities. Her commitment to advancing human health and safety has made her a key figure in the field.

"I am honored to be recognized among such exemplary colleagues and to contribute to the evolution of safer, more sustainable practices in our industry," said Borton upon her nomination.

The contributions of both Borton and Coleman highlight the urgency and relevance of developing alternative testing methods that prioritize ethical considerations in research and testing.

Looking Ahead

As the 2026 Lush Prize approaches, it will shine a spotlight on innovative practices in toxicology and promote a future where non-animal testing methods are the norm rather than the exception. The implications of their research extend beyond mere academic interest; they pave the way for a transformation in health and safety protocols affecting millions across the globe.

Gradient, known for its unwavering commitment to environmental and risk sciences, stands at the forefront of these discussions, driving change through scientific excellence. As leaders in the consulting field, they aim to provide strategic solutions that safeguard both human health and the environment.

Join us in congratulating Lindsey Borton and Kelly Coleman for their outstanding achievements, and best of luck to all the finalists competing for the prestigious Lush Prize this year.